Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 73, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'catslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]Code Context
trigger_error($message, E_USER_DEPRECATED);
}
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.' $stackFrame = (int) 1 $trace = [ (int) 0 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php', 'line' => (int) 2421, 'function' => 'deprecationWarning', 'args' => [ (int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.' ] ], (int) 1 => [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) {}, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ], (int) 2 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php', 'line' => (int) 610, 'function' => 'printArticle', 'class' => 'App\Controller\ArtileDetailController', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 3 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 120, 'function' => 'invokeAction', 'class' => 'Cake\Controller\Controller', 'object' => object(App\Controller\ArtileDetailController) {}, 'type' => '->', 'args' => [] ], (int) 4 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php', 'line' => (int) 94, 'function' => '_invoke', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(App\Controller\ArtileDetailController) {} ] ], (int) 5 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php', 'line' => (int) 235, 'function' => 'dispatch', 'class' => 'Cake\Http\ActionDispatcher', 'object' => object(Cake\Http\ActionDispatcher) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 6 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Http\BaseApplication', 'object' => object(App\Application) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 7 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php', 'line' => (int) 162, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 8 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\RoutingMiddleware', 'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 9 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php', 'line' => (int) 88, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 10 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Routing\Middleware\AssetMiddleware', 'object' => object(Cake\Routing\Middleware\AssetMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 11 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php', 'line' => (int) 96, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 12 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 65, 'function' => '__invoke', 'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware', 'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {}, (int) 2 => object(Cake\Http\Runner) {} ] ], (int) 13 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php', 'line' => (int) 51, 'function' => '__invoke', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\ServerRequest) {}, (int) 1 => object(Cake\Http\Response) {} ] ], (int) 14 => [ 'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php', 'line' => (int) 98, 'function' => 'run', 'class' => 'Cake\Http\Runner', 'object' => object(Cake\Http\Runner) {}, 'type' => '->', 'args' => [ (int) 0 => object(Cake\Http\MiddlewareQueue) {}, (int) 1 => object(Cake\Http\ServerRequest) {}, (int) 2 => object(Cake\Http\Response) {} ] ], (int) 15 => [ 'file' => '/home/brlfuser/public_html/webroot/index.php', 'line' => (int) 39, 'function' => 'run', 'class' => 'Cake\Http\Server', 'object' => object(Cake\Http\Server) {}, 'type' => '->', 'args' => [] ] ] $frame = [ 'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php', 'line' => (int) 74, 'function' => 'offsetGet', 'class' => 'Cake\Http\ServerRequest', 'object' => object(Cake\Http\ServerRequest) { trustProxy => false [protected] params => [ [maximum depth reached] ] [protected] data => [[maximum depth reached]] [protected] query => [[maximum depth reached]] [protected] cookies => [[maximum depth reached]] [protected] _environment => [ [maximum depth reached] ] [protected] url => 'latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335/print' [protected] base => '' [protected] webroot => '/' [protected] here => '/latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335/print' [protected] trustedProxies => [[maximum depth reached]] [protected] _input => null [protected] _detectors => [ [maximum depth reached] ] [protected] _detectorCache => [ [maximum depth reached] ] [protected] stream => object(Zend\Diactoros\PhpInputStream) {} [protected] uri => object(Zend\Diactoros\Uri) {} [protected] session => object(Cake\Http\Session) {} [protected] attributes => [[maximum depth reached]] [protected] emulatedAttributes => [ [maximum depth reached] ] [protected] uploadedFiles => [[maximum depth reached]] [protected] protocol => null [protected] requestTarget => null [private] deprecatedProperties => [ [maximum depth reached] ] }, 'type' => '->', 'args' => [ (int) 0 => 'artileslug' ] ]deprecationWarning - CORE/src/Core/functions.php, line 311 Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421 App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74 Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51 Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]Code Contextif (Configure::read('debug')) {
trigger_error($message, E_USER_WARNING);
} else {
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-trace').style.display = (document.getElementById('cakeErr6826fe4b260cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6826fe4b260cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-code').style.display = (document.getElementById('cakeErr6826fe4b260cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-context').style.display = (document.getElementById('cakeErr6826fe4b260cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6826fe4b260cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6826fe4b260cd-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 17207, 'metaTitle' => 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey', 'metaKeywords' => 'medicines,Health', 'metaDesc' => ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...', 'disp' => '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 17207 $metaTitle = 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey' $metaKeywords = 'medicines,Health' $metaDesc = ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...' $disp = '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey | Im4change.org</title> <meta name="description" content=" -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug makers may dodge price control-Sushmi Dey</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />“In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />“Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />“This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify"> </div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /></div> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $maxBufferLength = (int) 8192 $file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php' $line = (int) 853 $message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]Code Context$response->getStatusCode(),
($reasonPhrase ? ' ' . $reasonPhrase : '')
));
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-trace').style.display = (document.getElementById('cakeErr6826fe4b260cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6826fe4b260cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-code').style.display = (document.getElementById('cakeErr6826fe4b260cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-context').style.display = (document.getElementById('cakeErr6826fe4b260cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6826fe4b260cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6826fe4b260cd-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 17207, 'metaTitle' => 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey', 'metaKeywords' => 'medicines,Health', 'metaDesc' => ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...', 'disp' => '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 17207 $metaTitle = 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey' $metaKeywords = 'medicines,Health' $metaDesc = ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...' $disp = '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey | Im4change.org</title> <meta name="description" content=" -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug makers may dodge price control-Sushmi Dey</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />“In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />“Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />“This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify"> </div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /></div> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $reasonPhrase = 'OK'header - [internal], line ?? Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]Notice (8): Undefined variable: urlPrefix [APP/Template/Layout/printlayout.ctp, line 8]Code Context$value
), $first);
$first = false;
$response = object(Cake\Http\Response) { 'status' => (int) 200, 'contentType' => 'text/html', 'headers' => [ 'Content-Type' => [ [maximum depth reached] ] ], 'file' => null, 'fileRange' => [], 'cookies' => object(Cake\Http\Cookie\CookieCollection) {}, 'cacheDirectives' => [], 'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-trace').style.display = (document.getElementById('cakeErr6826fe4b260cd-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6826fe4b260cd-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-code').style.display = (document.getElementById('cakeErr6826fe4b260cd-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6826fe4b260cd-context').style.display = (document.getElementById('cakeErr6826fe4b260cd-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6826fe4b260cd-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">> </span></span></code> <span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/> </span></code></span> <code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/> </span></span></code></pre><pre id="cakeErr6826fe4b260cd-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 17207, 'metaTitle' => 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey', 'metaKeywords' => 'medicines,Health', 'metaDesc' => ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...', 'disp' => '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> &ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> &ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> &ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> &nbsp; </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 17207 $metaTitle = 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey' $metaKeywords = 'medicines,Health' $metaDesc = ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...' $disp = '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control &mdash; to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />&ldquo;In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,&rdquo; says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla&rsquo;s popular anti-hypertension medicine Amlopres-AT and Intas Pharma&rsquo;s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />&ldquo;Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,&rdquo; says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. &ldquo;If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,&rdquo; Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy&rsquo;s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />&ldquo;This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,&rdquo; says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week&rsquo;s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify">&nbsp;</div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine.&nbsp; <br /></div>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-makers-may-dodge-price-control-sushmi-dey-17335.html"/> <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css" media="all"/> <title>LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey | Im4change.org</title> <meta name="description" content=" -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a..."/> <script src="https://im4change.in/js/jquery-1.10.2.js"></script> <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script> <script language="javascript" type="text/javascript"> $(document).ready(function () { var img = $("img")[0]; // Get my img elem var pic_real_width, pic_real_height; $("<img/>") // Make in memory copy of image to avoid css issues .attr("src", $(img).attr("src")) .load(function () { pic_real_width = this.width; // Note: $(this).width() will not pic_real_height = this.height; // work for in memory images. }); }); </script> <style type="text/css"> @media screen { div.divFooter { display: block; } } @media print { .printbutton { display: none !important; } } </style> </head> <body> <table cellpadding="0" cellspacing="0" border="0" width="98%" align="center"> <tr> <td class="top_bg"> <div class="divFooter"> <img src="https://im4change.in/images/logo1.jpg" height="59" border="0" alt="Resource centre on India's rural distress" style="padding-top:14px;"/> </div> </td> </tr> <tr> <td id="topspace"> </td> </tr> <tr id="topspace"> <td> </td> </tr> <tr> <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> <tr> <td width="100%"> <h1 class="news_headlines" style="font-style:normal"> <strong>Drug makers may dodge price control-Sushmi Dey</strong></h1> </td> </tr> <tr> <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3"> <div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />“In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />“Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />“This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify"> </div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /></div> </font> </td> </tr> <tr> <td> </td> </tr> <tr> <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;"> <form><input type="button" value=" Print this page " onclick="window.print();return false;"/></form> </td> </tr> </table></body> </html>' } $cookies = [] $values = [ (int) 0 => 'text/html; charset=UTF-8' ] $name = 'Content-Type' $first = true $value = 'text/html; charset=UTF-8'header - [internal], line ?? Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181 Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55 Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141 [main] - ROOT/webroot/index.php, line 39
<head>
<link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp' $dataForView = [ 'article_current' => object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> “In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> “Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> “This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ [maximum depth reached] ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ [maximum depth reached] ], '[dirty]' => [[maximum depth reached]], '[original]' => [[maximum depth reached]], '[virtual]' => [[maximum depth reached]], '[hasErrors]' => false, '[errors]' => [[maximum depth reached]], '[invalid]' => [[maximum depth reached]], '[repository]' => 'Articles' }, 'articleid' => (int) 17207, 'metaTitle' => 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey', 'metaKeywords' => 'medicines,Health', 'metaDesc' => ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...', 'disp' => '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />“In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />“Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />“This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify"> </div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /></div>', 'lang' => 'English', 'SITE_URL' => 'https://im4change.in/', 'site_title' => 'im4change', 'adminprix' => 'admin' ] $article_current = object(App\Model\Entity\Article) { 'id' => (int) 17207, 'title' => 'Drug makers may dodge price control-Sushmi Dey', 'subheading' => '', 'description' => '<div align="justify"> -The Business Standard<br /> <br /> <em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /> </em><br /> While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /> <br /> “In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /> <br /> A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /> <br /> For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /> <br /> “Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /> <br /> According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /> <br /> Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /> <br /> “This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /> <br /> The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula. </div> <div align="justify"> </div> <div align="justify"> <strong><em>Correction</em></strong> </div> <div align="justify"> <br /> This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /> </div>', 'credit_writer' => 'The Business Standard, 30 September, 2012, http://www.business-standard.com/india/news/drug-makers-may-dodge-price-control/488065/', 'article_img' => '', 'article_img_thumb' => '', 'status' => (int) 1, 'show_on_home' => (int) 1, 'lang' => 'EN', 'category_id' => (int) 16, 'tag_keyword' => '', 'seo_url' => 'drug-makers-may-dodge-price-control-sushmi-dey-17335', 'meta_title' => null, 'meta_keywords' => null, 'meta_description' => null, 'noindex' => (int) 0, 'publish_date' => object(Cake\I18n\FrozenDate) {}, 'most_visit_section_id' => null, 'article_big_img' => null, 'liveid' => (int) 17335, 'created' => object(Cake\I18n\FrozenTime) {}, 'modified' => object(Cake\I18n\FrozenTime) {}, 'edate' => '', 'tags' => [ (int) 0 => object(Cake\ORM\Entity) {}, (int) 1 => object(Cake\ORM\Entity) {} ], 'category' => object(App\Model\Entity\Category) {}, '[new]' => false, '[accessible]' => [ '*' => true, 'id' => false ], '[dirty]' => [], '[original]' => [], '[virtual]' => [], '[hasErrors]' => false, '[errors]' => [], '[invalid]' => [], '[repository]' => 'Articles' } $articleid = (int) 17207 $metaTitle = 'LATEST NEWS UPDATES | Drug makers may dodge price control-Sushmi Dey' $metaKeywords = 'medicines,Health' $metaDesc = ' -The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a...' $disp = '<div align="justify">-The Business Standard<br /><br /><em>The proposed pharma pricing policy may give room to drug makers to escape price control.<br /></em><br />While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation.<br /><br />“In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities.<br /><br />A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products.<br /><br />For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list.<br /><br />“Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati.<br /><br />According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said.<br /><br />Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control.<br /><br />“This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati.<br /><br />The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula.</div><div align="justify"> </div><div align="justify"><strong><em>Correction</em></strong></div><div align="justify"><br />This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. <br /></div>' $lang = 'English' $SITE_URL = 'https://im4change.in/' $site_title = 'im4change' $adminprix = 'admin'
include - APP/Template/Layout/printlayout.ctp, line 8 Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413 Cake\View\View::_render() - CORE/src/View/View.php, line 1374 Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927 Cake\View\View::render() - CORE/src/View/View.php, line 885 Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791 Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126 Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94 Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96 Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65 Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
![]() |
Drug makers may dodge price control-Sushmi Dey |
-The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control — to the extent that even if a company manufactures a combination drug containing two formulations under price control, it still circumvents the regulation. “In many cases, taking advantage of the escape route many manufacturers will just add a minute quantity of an irrelevant agent to convert a single-ingredient formulation into a fixed-dose combination,” says C M Gulati, editor, Monthly Index of Medical Specialities. A representative of a leading drug maker agrees many companies would be able to bypass the norm because they mostly sell combination products. For example, metoprolol and hydrochlorothiazide, both under the proposed price control, when combined in a fixed-dose combination, escape the price control benchmark. Many companies such as Astrazeneca and Ajanta Pharma manufacture the combination product under their respective brands, Betaloc-H and Met-XL-H, trade sources say. Similarly, Cipla’s popular anti-hypertension medicine Amlopres-AT and Intas Pharma’s Amtas-AT would bypass price control even as they contain amlodipine and atenolol, both of which are part of the 348 essential drug list. “Around 40 per cent of the total drugs sold in the country are fixed-dose combinations and they are not under price control. So, the whole purpose of the policy is defeated,” says Gulati. According to Amit Sengupta, the co-convenor of Jan Swasthya Abhiyan, a public health advocacy movement, such a loophole would not only result in companies migrating out of price control but have a larger implication on public health. “If the government does not bring combinations into price control, it will promote the proliferation of irrational combinations, which would be a bigger problem,” Sengupta said. Besides, the panel has recommended price control only on the basic formulations in any particular therapeutic area and left out various equivalent alternatives used to treat the same diseases. That would enable companies to escape price control by switching over to producing alternatives not part of the regulation. For instance, ethromycin, used to treat high blood pressure and under proposed price control, is currently being sold by drug makers such as Pfizer, Alembic and Ipca Laboratories. However, as soon as the policy comes into effect, these companies may start manufacturing alternatives such as fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril and trandolapril, which are all equivalents of ethromycin. Similarly, the anti-epileptic carbamazepine can be replaced by oxcarbazepine, whereas painkiller diclofenac can be replaced with aceclofenac. Currently, companies like Novartis, Dr Reddy’s Labs, Cadila Pharma and Ranbaxy manufacture some of these drugs that may come under price control. “This is a major loophole in the proposal. A class of drugs has got various molecules and you are bringing only one under price control. Of these 348 medicines, there is hardly any drug that does not have an alternative or rather a superior one,” says Gulati. The panel, headed by Sharad Pawar, finalised its recommendations on the proposed National Pharmaceutical Pricing Policy on Thursday. It will send its suggestions to the Cabinet in a week’s time, Pawar has said. Various health groups have opposed the proposed formula. Correction This article had wrongly mentioned enalapril as ethromycin, which has been corrected. It was also mentioned that Pfizer, Alembic and Ipca Labs sell the product which was wrong. Dr Reddy's and Cadila sell the medicine. |